CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Advanced Biomed Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Advanced Biomed Inc
401 Ryland St, Ste 200-A
Phone: (862) 120-510823p:862 120-510823 RENO, NV  89502  United States
Business Summary
Advanced Biomed Inc is a Taiwan-based company mainly engaged in the provision of assay products and services for cancer patients. The Company provides services include early screening and detection, diagnosis and staging, treatment selection, and patient outcome interventions for cancer using integrating semiconductor technology and biotechnology. The devices of the Company, A+Pre, AC-1000, A+CellScan, and A+SCDrop, and three corresponding microfluidic biochips, A+Pre Chip and AC-1000 CTC Enrichment Chip and A+CellScan Chip, are designed to provide rapid and affordable assay products and services to cancer patients. The Company also provides four matching immunostaining kits, A+CTCE, A+CTCM, A+EMT and A+CM, for determining and identifying the expression and cell type of the target protein. The Company also has product for early screening of lung cancer, the A+LCGuard Lung Cancer Early Screening Kit.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/20236/30/2022-----

Industries
SIC Code Description
8071 Medical laboratories
3845 Electromedical and electrotherapeutic apparatus
2835 In vitro and in vivo diagnostic substances

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Director of Investor Relations Alan..

General Information
Number of Employees: 40 (As of 3/31/2023)
Outstanding Shares: 99,000,000 (As of 3/31/2023)
Email Address: Info@advanbiomed.com


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, November 20, 2024